1 / 26

Neurosarcoidosis

Neurosarcoidosis. Duc Tran, M.D. September 2003. General. Multisystem granulomatous disease Etiology unknown Lungs, heart, bone, nervous system 1909 – Uveoparotid fever/cranial nerve palsies Incidence 0.85% whites, 2.4% blacks Children – more common in whites. Usually better prognosis

trung
Télécharger la présentation

Neurosarcoidosis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Neurosarcoidosis Duc Tran, M.D. September 2003

  2. General • Multisystem granulomatous disease • Etiology unknown • Lungs, heart, bone, nervous system • 1909 – Uveoparotid fever/cranial nerve palsies • Incidence 0.85% whites, 2.4% blacks • Children – more common in whites. Usually better prognosis • Prevalence 40/100,000 • Mortality 1-5%. Usually secondary to respiratory failure

  3. Clinical • Lungs involved most often (90%) • Lymph nodes (33%) • Liver (50-80%) • Skin (25%) • Eyes • Musculoskeletal (25-39%) • Endocrine

  4. Genetics • Higher prevalence first generation relatives • Familial clustering of cases • HLA-B8 UK, Italian, Czech • HLA-DR17 Scandinavian • Polymorphisms C-C chemokine receptor (monocyte chemoattractant protein)

  5. Etiology • HHV-8 • HIV • Mycobacterium • Borrelia • Propionibacterium acnes • Aluminum, beryllium, zirconium

  6. Immunology • Accumulation activated T cells and macrophages • Release of interferon gamma, interleukin-2, cytokines • Interaction sarcoid antigen with specific T cell receptor and antigen presenting cell to trigger inflammatory response

  7. Pathology • Noncaseating epitheliod cell granuloma • Accumulation of CD4 • Multinucleated giant cells may be present • Inflammation similar in all organs affected • Fibrosis leads to tissue damage

  8. Neurologic Involvement • Frequency 5-16% • Occurs at later age than systemic • Majority have systemic disease • Neurologic symptoms presenting features 50% cases • Acute – isolated CN or aseptic meningitis • Chronic – parenchymal, multi CN, hydrocephalus, PNS

  9. Neurologic Involvement • Series 68 pts CNS involvement 62% (optic, CN palsies increased rate to 72%. • Spinal 28% • Posterior Fossa 21% • Cognitive decline 10%

  10. Manifestations • Encephalopathy (14-30%) anxiety, dementia, vascular dementia • Mass lesions (3-26%). • Hypothalamic (10-26%) • Meningitis (8-40%). • Hydrocephalus (6-17%). • Seizures (18-34%) • Posterior Fossa (9-26%). • Spinal Cord (3-10%). • Peripheral Nerve (6-40%) • Muscle (9-23%)

  11. Diagnosis • Verification of systemic sarcoid • CT – hyperdense, enhance with contrast. Periventricular white matter lesions common • MRI sensitivity (82%). • PET • Gallium scans • VEP/BAEP • Kviem-Siltzbach (KT) 67-92% • Serum ACE may correlate with clinical disease • Biopsy if feasible

  12. Diagnosis • CSF nonspecific • CSF 80% abnormal • elevated cell count (<50 WBC/mm) • protein (<100 mg%) • elevated pressure • decreased glucose • CSF ACE level elevated 50% cases. ?Use (usually elevated with elevated protein) • IgG Index/Oliogoclonal Bands reported • Elevated CD4/CD8 ratio • Lysozyme/B2m elevated in half of patients

  13. Diagnosis • Multiple Sclerosis • Idiopathic Bell’s Palsy • Granulomatous Infections • Lyme • Vasculitis • Neoplasms • Meningeal Carcinomatosis • HIV/AIDS • Herpes Encephalitis

  14. Cranial Nerve • 37-61% • Facial nerve most often involved • CN VIII, Optic, Trigeminal • Other CNs less often involved leading to anosmia, disturbance of ocular movements, pharygeal/vocal cord involvement

  15. Meningeal Involvement • 60% of cases • Aseptic meningitis • Meningeal mass lesion • Obstructive or communicating hydrocephalus • Cranial neuropathies from basilar meningitis

  16. Parenchymal Disease • Clinical features depend on location • Hypothalmic – impairment of neuroendocrine system (thyroid, adrenal, sexual dysfucntion, sleep, temperature, electrolyte balance, appetite) • Mass lesions

  17. Encephalitis/Seizures • Delirium, psychiatric, memory disturbance • TIAs/vasculopathy • Seizures 20% of patients – generalized or focal • Seizures associated with poorer prognosis

  18. Peripheral System • PN – 15-18% of cases • Axonal sensorimotor most common • Mononeuritis multiplex, polyradiculopathy, GBS • Most are assymptomatic • Epineurium/perineurium involvement axonal degeneration • Endoneurium involvement demyelinating neuropathy

  19. Peripheral System • Muscle involvement is common. • Symptomatic – less 1% of systemic cases • Acute or chronic myopathy, myositis, intramuscular nodules, pseudohypertrophy • More common in women (4:1), especially postmenopausal

  20. Corticosteroids • Mainstay of treatment • Proposed mechanism • Inhibition of lymphocyte/mononuclear phagocytic activity • Inhibition of transcription of proinflammatory cytokines • Downregulation of cellular receptors • Interference with collagen synthesis • May not change natural history

  21. Treatment • Cyclosporine. • Azathioprine. • Methotrexate. • Cyclophosphamide • Radiation.. • Surgery

  22. Treatment • Tacrolimus (Prograf) – macrolide immunosuppresant. Inhibit T-cell activation • Sirolimus (Rapamune) – macrolide immunosuppressant. • Anticytokine therapy • Anticellular adhesion molecules • Gene therapy targeting proinflammatory cytokines

  23. Treatment • Consider combination therapy, refractory cases • Isolated facial palsies – favorable outcome • Certain cases, e.g. parenchymal involvement, may require longer course of treatment • Consider biopsy of intracranial lesions • Before initiating therapy • Refractory to treatment • Diagnosis unclear

  24. Treatment • Shunt in selected cases • Surgical resection rarely curative • Seizure control • Peripheral involvement treat if symptomatic

  25. Prognosis • Monophasic, relapsing, progressive • 2/3 neurologic symptoms may improve with treatment • Depends on location of involvement • 72% deterioration with spinal cord 18 months or more • Acute or subacute presentations have better prognosis than chronic • 1/3 may relapse • Mortality 8-12% if neurological involvement

  26. References • Zajicek JP. Neurosarcoidosis. Current Opinion in Neurology. 2000; 13:323-325. • Oksanen V. Neurosarcoidosis. Sarcoidosis. 1994; 11:76-79. • Gullapalli D, Phillips LH. Neurologic Manifestations of Systemic Disease. Neurologic Clinics. 2002; 20(1). • Mana J. Magnetic Resonance Imaging and Nuclear Imaging in Sacoidosis. Current Opinions in Pulmonary Medicine. 2002; 8(5): 457-463. • Scott TF. Neurosacoidosis: Progress and Clinical Aspects. Neurology. 1993; 43:8-12. • Kang S, Suh JH. Radiation Therapy for Neurosarcoidosis: Report of Three Cases from a Single Institution. Radiation Oncology Investigations. 1999; 7:309-312. • Nowak DA, Widenka DC. Neurosarcoidosis: a review if its intracranial manifestations. Journal Neurology. 2001; 248:363-372. • Zajicek JP, Scolding NJ, et al. Central Nervous System Sarcoidosis-diagnosis and management. Quarterly Journal of Medicine. 1999; 92:103-111.

More Related